Regeneron Pharmaceuticals, Inc.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. carries a market capitalization of 49.87B, placing it among publicly traded companies globally. Its enterprise value stands at 45.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Regeneron Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. has 103.14M shares outstanding.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 14.29. The price-to-sales ratio is 3.98, and the price-to-book ratio stands at 1.95.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 12.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.63 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Regeneron Pharmaceuticals, Inc. trades at an EV/FCF ratio of 12.43, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 45.59B versus a market cap of 49.87B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. maintains a current ratio of 3.34, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.54, indicating elevated leverage, while an interest coverage ratio of 78.91 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. posted a return on equity (ROE) of 14.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.60 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.83, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.05, useful for judging operating efficiency across full business cycles. The company generates approximately 818,403.33 in revenue per employee across its workforce of 15,334.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.75 indicates how many times Regeneron Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. recorded 676.40M in income tax expense. That works out to an effective tax rate of 16.21, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.17B, leaving 3.50B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 5, 2026, Regeneron Pharmaceuticals, Inc.'s stock has gained approximately 35.60% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. generated 12.55B in revenue and converted that into 3.50B in net income, yielding earnings per share of 32.65. EBITDA reached 3.53B, while operating income came in at 3.37B.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. holds 6.46B in cash and equivalents against 2.19B in total debt, resulting in a net debt position of -379.03M. Total book value stands at 25.62B, with working capital of 10.43B providing operational flexibility.

Regeneron Pharmaceuticals, Inc. produced 3.78B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -149.61M in capital expenditures, free cash flow totaled 3.63B - equivalent to 35.15 per share.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. posted a gross margin of 84.86, reflecting its pricing power and cost economics. The operating margin of 26.87 and net profit margin of 27.86 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. paid dividends of 2.96 per share. The dividend payout ratio of 8.74 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.01, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.71, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Regeneron Pharmaceuticals, Inc. shareholders.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. has an Altman Z-Score of 6.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.